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Abstract
The pathogenesis of ischemic stroke is a complex sequence of events including inflammatory reaction, for which the
microglia appears to be a major cellular contributor. However, whether post-ischemic activation of microglial cells has
beneficial or detrimental effects remains to be elucidated, in particular on long term brain plasticity events. The objective of
our study was to determine, through modulation of post-stroke inflammatory response, to what extent microglial cells are
involved in some specific events of neuronal plasticity, neurite outgrowth and synaptogenesis. Since microglia is a source of
neurotrophic factors, the identification of the brain-derived neurophic factor (BDNF) as possible molecular actor involved in
these events was also attempted. As a means of down-regulating the microglial response induced by ischemia, 3-
aminobenzamide (3-AB, 90 mg/kg, i.p.) was used to inhibit the poly(ADP-ribose) polymerase-1 (PARP-1). Indeed, PARP-1
contributes to the activation of the transcription factor NF-kB, which is essential to the upregulation of proinflammatory
genes, in particular responsible for microglial activation/proliferation. Experiments were conducted in rats subjected to
photothrombotic ischemia which leads to a strong and early microglial cells activation/proliferation followed by an
infiltration of macrophages within the cortical lesion, events evaluated at serial time points up to 1 month post-ictus by
immunostaining for OX-42 and ED-1. Our most striking finding was that the decrease in acute microglial activation induced
by 3-AB was associated with a long term down-regulation of two neuronal plasticity proteins expression, synaptophysin
(marker of synaptogenesis) and GAP-43 (marker of neuritogenesis) as well as to a significant decrease in tissue BDNF
production. Thus, our data argue in favour of a supportive role for microglia in brain neuroplasticity stimulation possibly
through BDNF production, suggesting that a targeted protection of microglial cells could represent an innovative approach
to potentiate post-stroke neuroregeneration.
Citation: Madinier A, Bertrand N, Mossiat C, Prigent-Tessier A, Beley A, et al. (2009) Microglial Involvement in Neuroplastic Changes Following Focal Brain
Ischemia in Rats. PLoS ONE 4(12): e8101. doi:10.1371/journal.pone.0008101
Editor: Colin Combs, University of North Dakota, United States of America
Received August 7, 2009; Accepted November 5, 2009; Published December 1, 2009
Copyright:  2009 Madinier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Conseil Regional de Bourgogne, France. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pgarnier@u-bourgogne.fr
Introduction
The pathogenesis of ischemic stroke is a complex sequence of
events including inflammatory reaction. Extensively studied over
the last decade, this phenomenon is characterized by the
involvement of several central and peripheral cell types as well
as a large number of inflammatory molecules [1–3]. Post-ischemic
inflammation includes the infiltration of polymorphonuclear
granulocytes, monocytes/macrophages into the injured brain
and the activation of astrocytes and microglia. Among these cells,
it is now well admitted that microglia appears to be a major
cellular contributor of post-ischemic inflammation [4]. After focal
ischemia, reactive microgliosis is characterized by a specific
chronology which includes a rapid microglial activation followed
by a massive expansion and migration of the resident microglial
cells. Several studies have shown that this initial intrinsic response
is followed by the recruitment of blood-born macrophages which
migrate after a delay of several days into the neuronal parenchyma
[5–7].
Whether microglial activation has beneficial or detrimental
effects on adjacent neuronal population is still controversially
discussed [8–10]. It has been proposed that these cells, through the
release of several harmful components such as IL-1b, TNF-a,
proteases and ROS species [11–14] can affect neuronal function
and promote neurotoxicity [1,11,15]. In addition, reducing
inflammatory response and microglial activation has conferred
neuroprotection in various models of neurodegeneration [16,17]
and has been shown to interfere with neurogenesis [18,19]. On the
other hand, there are also growing evidences showing that under
certain circumstances, microglia could be neuroprotective [20–22]
and could also promote adult neurogenesis [23,24]. Indeed,
microglia has been shown to be neurosupportive by the uptake of
glutamate [25], the removal of cell debris [26] and recently by the
ungulfment of polymorphonuclear neutrophiles [27]. In addition,
beyond this scavenger function, several evidences have demon-
strated that once activated or in proliferation, microglial cells are
also an important cellular source for the production of
neurotrophic factors such as IGF-1 [22,24] and BDNF [28].
Concerning this latter, evidences showing microglia as a source of
BDNF have been reported in in vitro studies [29] and after CNS
injuries such as traumatic brain injury [30] and striatal lesion [28].
To the best of our knowledge, there are surprisingly no data
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ischemia although this trophic factor has been designated to play a
central role in the CNS, as neuroprotective [31,32] and essential to
the stimulation of brain plasticity [33–35].
Thus, despite important progress in the understanding of
microglial activation, proliferation, phagocytosis function, cytokines
and growth factors production, the exact role of microglia is still
unclear. Even though several studies have been performed in order
to determine the function of these cells in neurogenesis [10], little is
known concerning the role of microglia in other long term post-
stroke brain plasticity events. In this context, the objective of our
study was to determine through modulation of inflammatory
response, to what extent microglial cells are involved in some
specific events of neuronal plasticity such as neurite outgrowth and
synaptogenesis. In addition, the identification of the neurotrophin
BDNF as possible molecular actor involved in these events was
attempted following ischemic injury. For this purpose, rats were
subjected to a photothrombotic ischemic stroke which is associated
with a strong and early microglial cells activation/proliferation
within the cortical lesion. The modulation of the inflammatory
response was performed by using a poly(ADP-ribose) polymerase-1
(PARP-1) inhibitor [3-aminobenzamide (3-AB), 90 mg/kg, i.p.].
Indeed, beside its function in DNA repair and its well established
participation in cell death through extensive activation after stroke
[36], PARP-1 has been shown to contribute to the activation of
transcription factors, among them the most important NF-kB that
has been designated to be essential to the upregulation of
proinflammatory genes and to lead to microglial activation/
proliferation [37,38]. Activated microglia was evaluated at serial
time points up to 1 month after ischemia by immunostaining for
OX-42 and ED-1. In parallel, the long term expression of two
neuronal plasticity proteins, GAP-43 as a marker of neuritogenesis
andsynaptophysinasa markerofsynaptogenesis aswellasthe tissue
production and cellular localization of BDNF were also analyzed.
Materials and Methods
Materials
3-Aminobenzamide (3-AB), protease inhibitor cocktail, phosphate
buffered saline (PBS), tris buffered saline (TBS) and all other reagent
grade chemicals were purchased from Sigma (Saint Quentin-
Fallavier, France). Acrylamide and bis-acrylamide, sodium dodecyl-
sulfate (SDS) and tween-20 were obtained from Bio-Rad (Ivry sur
Seine, France). The polyvinylidene difluoride (PVDF) membranes
were purchased from GE Healthcare (Orsay, France). The rabbit
polyclonal antibody raised against synaptophysin (RB-1461-P) and
themousemonoclonalantibodyrecognizingratGAP-43(Zymed33–
5000) were purchased respectively from Interchim (Montluc ¸on,
France) and Invitrogen (Cergy-Pontoise, France). The mouse
monoclonal CD11b (OX-42) that recognizes type 3 complement
receptors (MCA 275R) and the mouse monoclonal ED-1 raised
against rat lysosomal membrane antigen of activated macrophage/
microglia were obtained from AbD Serotec (Darmstadt, Germany).
Rabbit polyclonal anti-PAR recognizing poly(ADP)-ribose polymers
and anti-BNDF werepurchased from Calbiochem (Meudon, France)
and Chemicon (Molsheim, France), respectively. For secondary
antibodies, the Alexa Fluor 488- and 568-conjugated anti-rabbit and
–mouse antibodies were purchased from Molecular probes and the
horseradish peroxidase-conjugated anti-rabbit and –mouse antibod-
ies were obtained from Jackson ImmunoResearch Laboratories.
Animal Model
The experiments were carried out on 132 male Wistar rats
(290–310 g; Depre ´, Saint-Doulchard, France) and were conducted
according to the French Department of Agriculture guidelines
(license no. 21CAE035). The animals were housed five per cage
and kept under 12/12 h light/dark cycle and allowed ad libitum
access to food and water. Anesthesia was induced by i.p. injection
of chloral hydrate (400 mg/kg). Permanent focal ischemia was
induced by photothrombotic cortical occlusion as previously
described [39]. Briefly, anesthetized rats were infused for 20 s
with the photosensitizer dye rose bengal (20 mg/kg, i.v.) and a
laser beam was focused with an optic fiber (1 mm internal
diameter, emerging power 90 mW) through the skull on the right
hemisphere (1 mm posterior and 3 mm lateral relative to the
bregma). The laser system is a diode-pumped solid-state laser
(LCS-DLT-312, Opton Laser International, Orsay, France)
working at 532 nm. The skull was irradiated for 5 min, the
irradiation beginning 30 s before the dye injection.
Cortical Tissue Sampling
Anesthetized animals (400 mg/kg; chloral hydrate; i.p.) were
transcardially perfused with saline and then, brains were removed.
The cerebral cortices were quickly dissected and spread on glass
slide at 0uC. Two concentric samples of cortical tissue (P1, P2)
were punched with increasing internal diameter (4.6 and 9.5 mm)
as indicated in figure 1A. The diameter of the different punches
was chosen from the histological assessment of the ischemic lesion
[40]. At 24 h post-ictus when the lesion reaches maximal size, P1
corresponded to infarcted tissue only. At other post-ictus times, P1
corresponded to a mixed of infarcted and non infarcted tissue
Figure 1. Cortical tissue sampling and dimensions of ischemic
lesion. (A) Two concentric cortical samples (P1 and P2) were collected
using punches with increasing internal diameters (4,6 and 9,5 mm,
respectively). (B) At 24 h, P1 corresponded to lesioned tissue whereas
P2 rim corresponded to unlesioned tissue whatever the time point
considered. Infarcted area (Blank zone) evolves over the time after focal
photothrombotic ischemia. Ctrl=control.
doi:10.1371/journal.pone.0008101.g001
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whatever the time point considered as shown in figure 1B.
Immunoblot Analysis
After homogenization in seven volumes of lysis buffer [bi-distilled
water containing 50 mM Tris, 150 mM NaCl, 1 mM EGTA, 10%
glycerol, 1% triton X-100, 1% protease inhibitor (Sigma P8340)],
total protein extracts of the different punches were sonicated and
centrifuged at 10,0006g for 10 min. An aliquot of the supernatant
was kept for BCA protein measurement. Equal amounts of proteins
were dissolved in Laemmli solution (62.5 mM Tris–HCl (pH 6.8),
2% SDS, 10% glycerol, 0.001% bromophenol blue) with 2-
mercaptoethanol 5% and were heated at 85uC for 10 min. Proteins
were separated on 10–12% SDS–polyacrylamide gel electrophore-
sis (PAGE) according to [41]. Proteins were electrophoretically
transferred onto PVDF membrane (0.2 mm pore size) in cold
transfer buffer [10 mM NaHCO3, 3 mM Na2CO3 (pH 9.9) and
20% methanol]. The membranes were incubated overnight at 4uC
in 5% non-fat dry milk in TBS [20 mM Tris–HCl (pH 7.6) and
137 mM NaCl] containing 0.1% Tween 20 to block unspecific
binding. Membranes were washed, incubated for 4 h at room
temperature with specific primary antibodies at the following
dilutions: anti-synaptophysin (1/2000), anti-GAP-43 (1/2000) and
anti-b-actin (1/5000) and for 90 min with a horseradish peroxidase
(HRP)-conjugated anti-mouse IgG or anti-rabbit IgG (1/80000).
Protein–antibody complexes were visualized using the enhanced
chemiluminescence Western blotting detection system according to
the manufacturer’s protocol (GE Healthcare, Orsay, France). The
membranes werestripped and probed with an anti-b-actinantibody
(Sigma A5441) used as internal control. Synaptophysin, GAP-43
and b-actin band densities were determined by scanning densitom-
etry (Vilbert-Lourmat, Marne la Valle ´e, France). A computer-based
imaging system (Scion, NIH software, Bethesda, USA) was used to
measure the relative optical density of each specificband. Data were
expressed as arbitrary units.
Elisa
Cerebral levels of BDNF were determined with a commercial
ELISA kit (Chemikine, Chemicon, Molsheim, France) according
to the manufacturer’s instructions. Briefly, after dilution in the
homogenization buffer (1/10, v/v, see above for its composition),
50 ml of cerebral samples obtained from P1 and P2 punches were
incubated overnight in pre-coated microplates. They were then
incubated with biotinylated anti-BDNF antibody followed by
HRP-streptavidin. The oxidation of the enzyme substrate, the
3,39,5,59 tetramethylbenzidine (TMB), was measured at 450 nm
using a plate reader (vector-3 1420 multilabe, Perkin Elmer,
Waltham, USA). All assays were performed in triplicate. Cortical
BDNF levels were expressed in pg/mg of proteins.
Histology
Animals were anaesthetized with chloral hydrate (400 mg/kg, i.p.)
and the brains were washed by transcardiac perfusion with saline and
further perfused with 4% paraformaldehyde solution in 0.1 M
phosphate buffer (pH 7.5). The removed brains were postfixed in the
same fixative for 1 h and transferred for 48 h in a 20% sucrose
solution in PBS. They were then frozen in isopentane at 245uCa n d
stored at 280uC. Coronal sections (20-mmt h i c k )w e r ec u ti na
cryostat (HMSSO, Microm, Francheville, France) at 220uC.
Assessment of the Infarct Volume
Coronal sections (20-mm thick) were cut in a cryostat at 200 mm
intervals, collected on slides, and stained with Cresyl violet (0.4%,
pH 3.5). Injured cortical areas, i.e. unstained tissue as a reflection
of cell loss (Figure 2B), were measured using the computer image
analysis system (Scion, NIH software, Bethesda, USA) and the
distance between respective coronal sections were used to calculate
a linear integration for the lesion volume determination as
previously described [42].
Immunohistofluorescence
All brain sections from different animal groups were simulta-
neously run to ensure identical staining conditions. After rinsing in
PBS (pH 7.4), the sections were incubated for 2 h in 10% goat
serum (GS), 0.3% Tween-20 in PBS to block the non-specific
binding sites and thereafter overnight at 4uC with the primary
antibody in PBS containing 0.3% Tween-20 and 5% GS used at
the following dilutions: anti-PAR (1/250), anti-OX-42 (1/150),
anti-ED-1 (1/150), anti-BNDF (1/100). For BDNF detection, pre-
treatment with proteinase K was used for antigen retrieval (10 mg/
ml, 10 min). For cellular localization of PAR and BDNF
expression in neurons and microglia, double immunohistofluores-
cence experiments have been performed by the simultaneous
incubation of either the rabbit polyclonal antibodies recognizing
Figure 2. Temporal evolution of infarct volume: effect of 3-AB
treatment. (A) Measurements of infarct volume (mm
3) were performed
at 4 h, 24 h, 8 d, 15 d and 30 d after the onset of ischemia. 3-AB
(90 mg/kg) was given (i.p.) right after the induction of photothrombotic
ischemia. Values are expressed as means6S.E.M. n in bracket indicates
the number of animals in each experimental condition. (B) Represen-
tative photograph of a brain section stained with Cresyl violet after 24 h
of ischemia. The injured cortical area is unstained as the reflection of
cell loss. Scale bar=2.5 mm.
doi:10.1371/journal.pone.0008101.g002
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NeuN or OX-42 at 4uC overnight. After 4 washes, antibody
visualization was achieved by the incubation for 3 h at room
temperature with Alexa 488-conjugated anti-mouse and/or Alexa
568-conjugated anti-rabbit IgGs (1:1000). Negative controls were
prepared by omitting the primary antibodies. The sections were
then coverslipped with a fluorescent mounting medium and
observed with an epifluorescent microscope (Eclipse E600, Nikon).
Treatment
The 3-aminobenzamide (3-AB) was dissolved in DMSO (1 mg/
ml). The DMSO solution was then diluted (1/100) in NaCl 0.9%.
The 3-AB (90 mg/kg) was administered by i.p. route just after the
onset of ischemia. The effects of 3-AB treatment were measured at
different time points between 4 h and 1 month post-ictus and
compared with those of corresponding vehicle.
Quantification and Statistical Analysis
All assessments were performed by an observer blinded to the
experimental conditions. The OX-42 immunoreactive cells were
counted in the infarcted cortical area at 206magnification using
an epifluorescence microscope in 3 coronal sections at 21.60,
21.00, 20.40 mm from the bregma. Cells were counted
continuously in 8 horizontal and 6 vertical fields passing by the
center of the lesion using a 0.090 mm
2 square grid. The final
results were expressed per mm
2.
A l lv a l u e sw e r ee x p r e s s e da sm e a n s 6S.E.M. of n rats (six to eleven
animals in each group). Comparisons among groups of rats were made
using non-parametric Kruskal–Wallis test followed by Mann–Whitney
for independent variables. Statistical significance was set at P,0.05.
Results
Infarct Volume and PARP-1 Activation
The infarct volume measurements were performed 4 h, 24 h,
8 d, 15 d and 30 d after the onset of ischemia. As shown in
figure 2, photothrombotic ischemia leads in the early times (4 and
24 h) to an enlargement of the cortical lesion reaching a maximal
value of 24,25 mm
3 at 24 h. Consistent with previous data
[40,42], this first phase corresponds to the maturation of the
infarction whereas at longer time points (8, 15 and 30 d), the
infarct volumes decrease time-dependently until 3,90 mm
3 at
30 d, the last time point considered in our study.
In our experimental conditions, photothrombotic ischemia
leads to PARP-1 activation at 4 h and 24 h after the onset of
ischemia as evidenced by a marked PAR immunostaining, the
enzymatic product of PARP-1 (Fig. 3A). The staining was found
maximal at 4 h as compared to 24 h of ischemia and
disappeared at longer time points (data not shown). Cellular
localization of PAR formation was assessed in neurons and
microglia by double immunostaining experiments (Fig. 3B and
3C, respectively). Colocalization for PAR and NeuN revealed
that PAR formation in neurons was found maximal at 4 h of
ischemia as compared to 24 h (Fig. 3B). Conversely, PAR
formation in microglial cells appeared only after 24 h of
ischemia (Fig. 3C). Indeed, no PAR/OX-42 double-labeled cells
were observable at 4 h of ischemia.
Consistent with a rapid PARP-1 activation described after focal
ischemia [43], the PARP-1 inhibition was performed by 3-AB i.p.
injection right after the induction of photothrombotic ischemia.
Treatment with 3-AB produced an important decrease in PAR
immunostaining at 4 h and resulted in an almost disappearance of
poly(ADP-ribose) at 24 h (Fig. 3A), which demonstrates a reduced
capacity for PARP-1 activation in 3-AB treated animals and
validates our pharmacological treatment. Despite this effective
inhibition, the 3-AB treatment (90 mg/kg, i.p.) did not produce
any significant reduction in infarct volume and thus, whatever the
kinetic points considered. Finally, to ascertain the absence of
neuroprotection in 3-AB treated animals, the neuronal density was
also assessed at 24 h. There was no variation between the two
groups of animals (data not shown).
OX-42 and ED-1 Immunostaining
OX-42. Microglia/macrophages activation was assessed by
OX-42 expression. As shown in figure 4, our data revealed that
ischemia induces a robust microglia/macrophages activation
observable as soon as 4 h, the earliest time point investigated in
our study. At this time, OX-42 staining evidenced positive cells
with a ramified morphology, homogenously distributed in the
lesion (Fig. 4A1–2). After 24 h of ischemia, the staining was
located in the boundary of the lesion and indicated the presence of
two distinct cellular morphologies, stellate-shaped and rounded
amoeboid cells (Fig. 4C1–2). At longer time points (8, 15 and
30 d), OX-42-positive cells exposed an amoeboid cellular
morphology only and populated the whole infarcted area
(Fig. 4E, G, I). Since microglia and hematogenous macrophages
can adopt both ramified and amoeboid appearance [6], these two
cellular types are undistinguishable as far as no discriminating
cellular markers are available. However, based on studies using
toxic liposomes depleting hematogenous macrophages [5] or GFP
transgenic bone marrow chimeric mice [6,7] we can assume that
in our experimental conditions, early OX-42 and ED-1 staining
observed in a very hypo-perfused area is attributable to local
resident microglia while at longer time points (8, 15 and 30 d),
these markers can be expressed by both types of cells.
In our experimental conditions, PARP-1 inhibition by 3-AB
treatment was associated with a very important decrease in OX-42
staining at 4 h (Fig. 4B1–2) and 24 h (Fig. 4D1–2) of ischemia as
compared to vehicle treated animals. Indeed, the number of OX-
42 positive cells was significantly reduced by ,75% at 4 h and
,63% at 24 h of ischemia following 3-AB treatment (Table 1).
These results showed that PARP-1 inhibition induces a robust
decrease in resident microglial cells activation. On the other hand,
no differences were observable after 8 d of ischemia between
vehicle and 3-AB treated groups of animals (Fig. 4E, F, G, H, I, J
and table 1).
ED-1. Because round amoeboid morphology can be
associated with phagocytic capacity of activated local microglia
and blood-born monocytes derived macrophages, the expression
of lysosomal protein ED-1 was studied (Fig. 5). Our data show
almost no ED-1 immunostaining in the early times of ischemia
(4 h, 24 h; Fig. 5A1–2, C1–2), which is in agreement with the lack
of phagocytic activity known during the ramified state in OX-42
positive cells. In the line with the few amoeboid cells observed after
OX-42 staining in the vehicle treated group at 24 h, a few number
of ED-1 positive cells were detected at this time of ischemia
(Fig. 5C1–2). At longer time points, the pattern of ED-1 staining
was similar to that observed with OX-42 marker with an intense
staining within the infarcted zone. The similar distribution
between these two markers reveals that most of the amoeboid
cells have acquired phagocytic properties.
Treatment with 3-AB did not produce important differences in
term of ED-1 expression. In the early times, we were able to detect
the disappearance of the few ED-1 cells stained at 24 h (Fig. 5D1–
2) whereas at longer time points, no marked differences were
observable between vehicle and 3-AB treated groups of animals
(Fig. 5E, F, G, H, I, J).
Microglia and Neuroplasticity
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Since neuroplastic changes have been shown to be a delayed
phenomenon [44], GAP-43 and synaptophysin expression were
investigated by western blotting experiments in the two concentric
samples of cortical tissue P1 and P2 at longer time points of
ischemia (8, 15 and 30 d).
As shown in figure 6, photothrombotic ischemia led to a
significant and sustained increase in post-ischemic GAP-43
expression at 8, 15 and 30 d in P1 (Fig. 6A) and at 15 and 30 d
in P2 (Fig. 6B) as compared to control values.
After 3-AB treatment, our results indicated that the
expression of GAP-43 was significantly reduced in both P1
and P2 punches as compared to vehicle treated group of
animals. The expression of GAP-43 was found significantly
repressed in P1 at 30 d (241%, Fig. 6A) and in P2 at 8 d only
(223%, Fig. 6B).
Concerning synaptophysin expression, our results also showed
that photothrombosis led to a significant increase in this protein
expression in P1 at 15 and 30 d (Fig. 7A) and in P2 at 30 d
(Fig. 7B) as compared to control values.
In 3-AB treated animals, the increase in synaptophysin
expression was abrogated in both P1 and P2 cortical samples.
The expression was found significantly lower in P1 at 15
and 30 d (221% and 239%, respectively, Fig. 7A) and in
P2 at 30 d (244%, Fig. 7B) as compared to vehicle treated
animals.
Figure 3. Effect of 3-AB treatment on PARP-1 activation and PAR/NeuN, PAR/OX-42 immunocolocalization. (A) PARP-1 activation,
evidenced by PAR immunostaining, was performed on coronal sections of rats submitted to 4 h and 24 h of ischemia and treated with vehicle or
with 3-AB. A marked decrease in PAR formation was observable after 3-AB treatment. (B) Immunocolocalization for PAR and NeuN was
performed at 4 h and 24 h of ischemia. Arrows show double-positive cells. Ischemia-induced PAR formation in neurons is predominant at 4 h.
(C) Immunocolocalization for PAR and OX-42 was performed at 4 h and 24 h of ischemia. Arrows show double-positive cells. Ischemia induces
PAR formation in OX-42 positive cells at 24 h only. Photomicrographs are representative of 6 to 11 animals at each time point. Scale
bars=50 mm.
doi:10.1371/journal.pone.0008101.g003
Microglia and Neuroplasticity
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ELISA. The ELISA assessment of tissue BDNF level was
performed in each cortical punch (P1/P2, Fig. 8A). Our data
revealed that photothrombotic ischemia induces an early increase
in BDNF production in these two samples. As compared to control
levels (160 and 167 pg/mg in P1 and P2, respectively), post-
ischemic BDNF production increased significantly by 71% and
53% at 4 h and by 296% and 176% at 24 h. After 8 days of
ischemia, the cortical level of BDNF returned to control values.
Following 3-AB treatment, the increase in BDNF levels was
significantly attenuated in the lesioned area P1 only, after both 4
and 24 h of ischemia. The reduction was modest at 4 h (12%)
Figure 4. Time course of microglial/macrophages activation after ischemia: effect of 3-AB treatment. Microglial/macrophages activation
was assessed at 4 h, 24 h, 8 d, 15 d and 30 d of photothrombotic ischemia by immunostaining using anti-OX-42 antibody, recognizing type 3
complement receptors. Rats treated with 3-AB showed an important decrease in microglial/macrophages activation in the acute phase of ischemia
(B1–2 and D1–2). At longer time points, no differences were observed between vehicle (E, G, I) and 3-AB treated animals (F, H, J). Photomicrographs
are representative of 6 to 11 animals at each time point. Scale bar=200 mm in panels 1, 40 mm in panels 2 and 50 mm (insert).
doi:10.1371/journal.pone.0008101.g004
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vehicle treated animals.
BDNF and OX-42 immunocolocalization. To further
evaluate the role of microglia in BDNF production,
immunohistofluorescence for OX-42 and BDNF expression was
performed after 24 h of ischemia. As shown in figure 8B,
colocalization experiments indicated that OX-42-positive cells
located in the lesioned tissue, expressed BDNF. Nevertheless, the
double immunostaining revealed that the colocalization was only
partial since only a third of OX-42-positive cells produced BDNF.
As already mentionned, 3-AB treatment greatly reduced OX-42
immunostaining. Accordingly, BDNF-positive microglial cells
were hardly identified as compared to vehicle treated animals.
BDNF and NeuN immunocolocalization. Neuronal
expression of BDNF was assessed by immunohistofluorescence
for NeuN and BDNF after 24 h of ischemia. As shown in
figure 8C, colocalization experiments indicated that most of the
remaining neurons in the lesioned tissue expressed BDNF.
Following 3-AB treatment, a similar pattern of expression was
found as compared to vehicle treated animals (Fig. 8C).
Discussion
Our study reveals that the decrease in acute microglial
activation was associated with a long term down regulation of
synaptophysin and GAP-43 expression and to a significant
decrease in BDNF production. Taken together, our data argue
in favour of an important role for microglia in brain neuroplas-
ticity stimulation possibly through BDNF production.
In order to investigate the role of microglial cells in the
stimulation of neuroplastic changes, PARP-1 inhibition was used
as a means of down-regulating the microglial response induced by
ischemia. PARP-1 is a nuclear enzyme that normally functions to
facilitate DNA repair. It is also well established that extensive
PARP-1 activation promotes cell death through processes
involving energy depletion and the release of apoptosis-inducing
factor [45–47]. In our study, the choice of a strategy targeting
PARP-1 activation was based on previous studies showing that
PARP-1 is also an essential component in the regulation of
inflammatory response through its function as a coactivator of NF-
kB [37,48,49]. Our data show that photothrombotic focal
ischemia was associated with an early PARP-1 activation
occurring within the first 24 h with a maximal intensity observed
at 4 h after the onset of ischemia which is consistent with previous
reports [50]. Double immunostaining for PAR and NeuN or OX-
42 revealed that PAR formation in neurons was an early process as
compared to that observed in microglial cells. Indeed, PAR
formation in neurons was visible with a maximal intensity after 4 h
whereas it appeared only after 24 h of ischemia in microglial cells.
Our results are in agreement with previous data showing a rapid
PARP-1 activation in neurons after a focal brain ischemia [43] and
are also consistent with previous reports showing an activation of
PARP-1 in microglial cells [19,37]. Interestingly, despite the
effective PARP-1 inhibition evidenced by a strong decrease in
PAR staining, no significant differences in term of temporal
evolution of lesion size between vehicle and 3-AB treated animals
were observed. Noteworthy, the relative high dose of 3-AB
(90 mg/kg, i.p.) was purposely used in our experimental conditions
in order to target the inflammatory response only. Such a choice
was initially based on study showing that 3-AB is no more
neuroprotective beyond 80 mg/kg (i.p.) following MCAO in mice
[51]. Indeed, since the inflammatory reaction intensity is closely
related to the extent of the lesion, the investigation of the role of
microglial cells activation would have been inappropriate if a
marked decrease in the inflammatory reaction was found to be
associated with a strong and significant neuroprotection. The lack
of protective effects observed in studies using high doses of 3-AB
and its derivatives is not fully understood. It has been suggested
that benzamide could produce non-specific effects counteracting
with glucose metabolism, nucleic acid and protein synthesis [36].
However, since similar U-shaped dose-response curve has been
observed with structurally distinct PARP inhibitors such as 3,4-
dihydro 5-[4-(1-piperidinyl) butoxy]-1(2H)-isoquinolinone (DPQ)
in response to cerebral ischemia [52], it can be hypothesized that
high doses of PARP-1 inhibitors could impair DNA repair in the
peri-infarcted area that otherwise would have been rescued.
Finally, a robust and important decrease of OX-42 and ED-1
staining was observed in 3-AB treated animals in the early phase of
ischemia, confirming that PARP-1 inhibition is an efficient
approach for the modulation of local resident microglial activation
and proliferation.
One of the most striking finding of this work is that the
repression of microglial activation and proliferation in the acute
stage of ischemia is associated with a significant decrease in the
long term expression of neuronal plasticity proteins in the vicinity
of the lesioned area. Indeed, the expression of GAP-43, an
intracellular growth protein playing a role in sprouting, neuronal
pathfinding and branching [53] and the expression of synapto-
physin, an integral membrane protein of synaptic vesicles, widely
used as an immunohistological marker for the determination of
synaptogenesis [54] were both significantly reduced in 3-AB
treated animals as compared to vehicle treated animals. Concern-
ing GAP-43 expression, 3-AB treatment induces a reduced
expression already significant at 8 d and at one month post-
ischemia whereas statistical differences were found for synapto-
physin expression at longer time points (15 and 30 d of ischemia)
between the two groups of animals. Thus, our results suggest that
limiting the early microglial activation is associated with a decrease
in neurite outgrowth and synaptogenesis that normally occurred
after brain injuries [44,55–57]. This raises the possibility that
microglial cells play an important role in the reorganization of the
tissue surrounding the lesioned area.
Among the neurosupportive coupounds synthesized by microg-
lia, experimental evidences point out to BDNF as an appealing
candidate. In the past decade, BDNF has been involved in
learning, memory and neuroplasticity [58,59]. In addition,
exogenous treatment with BDNF or exposing animals to enriched
housing or exercise regimens, which also increases BDNF,
enhances behavioral recovery after brain injury [33,60,61].
Moreover, blocking BDNF through antisense or immunoadhesin
chimera (TrkB-IgG) strategies negates exercice-induced cognitive
improvement after focal ischemia [62] or traumatic brain injury
[63]. As assessed by ELISA, our study showed that photothrom-
botic ischemia is associated with a significant and robust increase
in BDNF production within the infarct zone at 4 h and 24 h of
Table 1. Number of OX-42 positive cells.
Time of ischemia 4 h 24 h 8 d 15 d 30 d
Vehicle 208620 113616 945632 460653 320636
3-AB 54612* 4268* 938645 539639 262642
Number of OX-42 positive cells after 4 h, 24 h, 8 d, 15 d and 30 d of ischemia in
the infarcted area. Data represented the number of OX-42 positive cells par
mm
2 and are expressed as means6S.E.M. from 6 to 11 animals.
*P,0.05 vs vehicle treated animals.
doi:10.1371/journal.pone.0008101.t001
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levels in the hemisphere ipsilateral to a focal photothrombotic
lesion in rats [64]. In addition, our immunohistological experi-
ments specify for the first time after a focal ischemia, that
approximately a third of microglial cells express BDNF after 24 h
of photothrombotic ischemia. Concerning this partial BDNF
expression, it can be hypothesized that among microglial cells
populating the brain lesion, coexist several subpopulations with
Figure 5. Time course of microglial/macrophages phagocytic activity after ischemia: effect of 3-AB treatment. Immunostaining for
phagocytic activity (microglia/macrophages) was performed using anti-ED1 antibody at 4 h, 24 h, 8 d, 15 d and 30 d of photothrombotic ischemia.
Note the absence of staining at 4 h in vehicle (A1–2) and 3-AB treated animals (B1-2). Rats treated with 3-AB (D1–2) showed a decrease in ED-1
staining at 24 h as compared to vehicle treated animals (C1–2). At longer time points, no differences were observed between vehicle (E, G, I) and 3-AB
treated animals (F, H, J). Photomicrographs are representative of 6 to 11 animals at each time point. Scale bar=200 mm in panels 1 and 40 mmi n
panels 2.
doi:10.1371/journal.pone.0008101.g005
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highly complex (ambivalent) microglial response in damage
formation, inflammation and repair after stroke. Following 3-AB
treatment, BDNF levels are significantly decreased by 30% and
microglial cells expressing BDNF hardly identified as compared to
vehicle treated animals. This only ,30% decrease in BDNF levels
as compared to the two-third decrease in microglial cells number
in 3-AB treated animals can be explained by the fact that BDNF
remains expressed by neurons. Consistently, our immunohistolog-
ical experiments reveal that both groups of animals exhibit a
similar BDNF staining in neurons. Such a neuronal expression of
BDNF is in agreement with previous studies reporting that brain
Figure 6. Time course of GAP-43 expression after ischemia: effect of 3-AB treatment. Western blots were prepared after 8 d, 15 d and
30 d of ischemia from P1 (A) and P2 (B) samples. Representative immunoblots are shown and densitometric analysis was performed after
normalization of GAP-43 expression on b-actin levels. Photothrombotic ischemia induces an increase in GAP-43 expression from 8 d of ischemia in P1
and 15 d in P2. 3-AB treatment repressed GAP-43 expression in P1 at 30 d. In P2, the overall GAP-43 expression was lower in 3-AB treated animals but
a significant decrease was found at 8 d only. Values are expressed as means6S.E.M. and are representative of 5 to 6 animals. (
# P,0.05 vs ctrl (sham
operated animals); *P,0.05 vs vehicle treated animals).
doi:10.1371/journal.pone.0008101.g006
Figure 7. Time course of synaptophysin expression after ischemia: effect of 3-AB treatment. Western blots were prepared after 8 d, 15 d
and 30 d of ischemia from P1 (A) and P2 (B) samples. Representative immunoblots are shown and densitometric analysis was performed after
normalization of synaptophysin expression on b-actin levels. Photothrombotic ischemia induces an increase in synaptophysin expression in P1 after
15 d and 30 d of ischemia and in P2 after 30 d. 3-AB treatment abrogates synaptophysin induction in P1 after 15 d and 30 d of ischemia and in P2
after 30 d. Values are expressed as means6S.E.M. and are representative of 5 to 6 animals. (
# P,0.05 vs ctrl (sham operated animals); *P,0.05 vs
vehicle treated animals).
doi:10.1371/journal.pone.0008101.g007
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evidenced by upregulation of BDNF mRNA or protein levels in
neurons within and around the lesion [64–66].
Although not investigated directly here, BDNF production may
be coupled to GAP-43 and synaptophysin inductions in several
ways. Indeed, in a model of cervical axotomy, BDNF injection has
been reported to stimulate GAP-43 expression and consequently
axogenesis and repair [67]. Moreover, a very recent study
performed on cortical culture using GAP-43 knockout animals
directly shows that GAP-43 is necessary to the neurotrophic effects
of BDNF [68]. In this study, GAP-43 was identified as a common
mediator of the plastic regeneration effect of BDNF. At the synaptic
level,BDNFhasbeenshowntobe important forsynaptogenesisand
to synaptic ultra structural composition in developing and adult
brain [35,69]. In addition, treatment using statin that induces
BDNF up-regulation is linked to an increase in synaptophysin
expression and to a significant improvement in functional recovery
[55]. Consistently, blocking BDNF action abrogates exercice-
induced synaptophysin expression [70]. Likewise, BDNF knockout
mice have a reduced level of synaptophysin in hippocampal
synaptosomes [71]. Finally, even though our study and others
suggest that BDNF is a preponderant compound in mediating post-
ischemic neuronal plasticity processes, it is important to underline
that other molecules besides BDNF such as IGF-1 [22,24], GDNF
[72,73], thrombospondins [74] or erythropoietin [75,76], which are
also produced by microglial cells, have been reported to promote
post-stroke plasticity events. Thus, it is likely that neuroplasticity
processes are orchestrated by several compounds, BDNF being one
of these pro-neuroplastic factors.
In conclusion, the present findings imply a supportive role for
microglial cells in the induction of neuroplastic changes after
ischemia through the production of BDNF. Although important
progress has been made in the comprehension of microglial cells
function, the identification of the mechanisms that determine
microglia accomplishing destructive or constructive role in the
CNS is a prerequisite in elaborating future strategies that would
maintain and sustain the trophic support provided by microglial
cells. A targeted protection of neurosupportive microglial cells
could represent a novel and exciting approach to potentiate post-
stroke neuroregenerative responses.
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Figure 8. Time course of BDNF production after ischemia and
BDNF/OX-42 immunocolocalization: effect of 3-AB treatment.
(A) Elisa measurements of BDNF production in P1 and P2 samples were
performed at 4 h, 24 h, 8 d, 15 d and 30 d of ischemia. Photothrom-
bosis induces a significant increase in BDNF production in both P1 and
P2 at 4 h and 24 h of ischemia. Note that the production was found
maximal in P1 at 24 h. Rats treated with 3-AB showed a significant
reduction in BDNF production in P1 at 4 h and 24 h of ischemia. Values
are expressed as means6S.E.M. and are representative of 5 to 6 animals.
(
# P,0.05 vs ctrl (sham operated animals); *P,0.05 vs vehicle treated
animals). (B) Immunocolocalization for OX-42 and BNDF was performed
at 24 h of ischemia. Arrows show double-positive cells. Ischemia
induces expression of BDNF in some OX-42 - positive cells. Rats treated
with 3-AB showed an almost complete disappearance of double
positive cells. (C) Immunocolocalization for NeuN and BDNF was
performed at 24 h of ischemia. Arrows show double-positive cells.
Ischemia induces expression of BDNF in neurons. Rats treated with 3-AB
exhibited a similar co-immunostaining. Photomicrographs are repre-
sentative of 6 to 11 animals. Scale bars=50 mm.
doi:10.1371/journal.pone.0008101.g008
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